Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Last updated: March 24, 2023
Sponsor: The George Washington University Biostatistics Center
Overall Status: Completed

Phase

3

Condition

Pregnancy

Lung Injury

Miscarriage

Treatment

N/A

Clinical Study ID

NCT01222247
HL98354-HD36801-ALPS
U10HD027915
U10HD040485
U10HD068268
U10HD040500
U10HD040544
U10HD036801
U10HD053097
U10HD021410
U10HD027869
U10HD034208
U01HL098354
U10HD053118
U10HD040560
U10HD034116
U10HD040545
U01HL098554
U10HD068258
U10HD068282
U10HD027917
U10HD040512
  • Female
  • Accepts Healthy Volunteers

Study Summary

This is a randomized placebo controlled trial to evaluate whether antenatal corticosteroids can decrease the rate of neonatal respiratory support, thus decreasing the rate of NICU admissions and improving short-term outcomes in the late preterm infant. The use of antenatal corticosteroids has been shown to be beneficial in women at risk for preterm delivery prior to 34 weeks but has not been evaluated in those likely to deliver in the late preterm period

Eligibility Criteria

Inclusion

Inclusion Criteria: Singleton Pregnancy. A twin pregnancy reduced to singleton (either spontaneously ortherapeutically) before 14,0 weeks by project gestational age is acceptable Gestational age at randomization between 34,0 weeks and 36,5 weeks confirmed by studycriteria High probability of delivery in the late preterm period (any one of the following):

  • Membrane rupture as defined by the occurrence of any two of the following: pooling offluid in the vaginal vault, positive Nitrazine test, ferning of vaginal fluid,positive AmniSure test; or any one of the following: indigo carmine pooling in thevagina after amnioinfustion, visible leakage of amniotic fluid from the cervix or
  • Preterm labor with intact membranes. Preterm labor is defined as at least 6 regularuterine contractions in an observation period of no more than 60 minutes and at leastone of the following: cervix greater than or equal to 3cm dilated or at least 75%effaced or
  • Planned delivery by induction of labor or cesarean section in no less than 24 hoursand no more than 7 days, as deemed necessary by the provider. An induction must bescheduled to start by 36,5 weeks at the latest, whereas a cesarean delivery must bescheduled by 36,6 weeks at the latest. Therefore the latest gestational age forrandomization is 36,4 weeks for a planned induction. The planned delivery may be forany indication, such as the following: prior myomectomy, prior classical cesarean,intrauterine growth restriction (IUGR), oligohydramnios, preeclampsia, nonreassuringfetal heart rate tracing warranting delivery, abruption, placenta previa

Exclusion

Exclusion Criteria:

  1. Any prior antenatal corticosteroid course during the pregnancy because of potentialcontamination of the placebo group
  2. Candidate for stress dose corticosteroids because of chronic steroid therapy toprevent suppression of adrenal gland, because of potential contamination of theplacebo group
  3. Twin gestation reduced to a singleton gestation at or after 14 weeks 0 days by projectgestational age either spontaneously or therapeutically
  4. Fetal demise, or known major fetal anomaly, including cardiac anomaly and hydrops
  5. Maternal contraindication to betamethasone: hypersensitivity reaction to anycomponents of the medication, idiopathic thromboycytopenic purpura, systemal fungalinfection in case of exacerbation by betamethasone, use of amphotericin B due to thepossibility of heart failure with concomitant betamethasone
  6. Pre-gestational diabetes - exclude if the patient was on medication (insulin,glyburide) prior to pregnancy
  7. Delivery expected within 12 hours of randomization, because of insufficient time ofcorticosteroids to confer benefit, including any of the following: A. Rupture of Membranes (ROM) does not satisfy protocol criteria - exclude if thepatient being evaluated for Preterm Premature Rupture of Membranes (pPROM), does nothave preterm labor or planned delivery and does not satisfy the spontaneous membranerupture criteria (any 2 of: positive Nitrazine test, pooling of fluid in the vaginalvault test or ferning of vaginal fluid; or indigo carmine pooling in the vagina afteramnioinfusion; or visible leakage of amniotic fluid from the cervix) B. Rupture of themembranes in the presence of more than 6 contractions per hour or cervical dilation of 3 cm or more, unless oxytocin was withheld for at least 12 hours (other inductionagents allowed) C. Chorioamnionitis - exclude if patient is diagnosed withchorioamnionitis D. Cervical dilation ≥ 8 cm E. Evidence of non-reassuring fetalstatus requiring immediate delivery
  8. Participation in another interventional study that influences neonatal morbidity andmortality
  9. Participation in this trial in a previous pregnancy
  10. Delivery at a non-network hospital
  11. At 36, 0 weeks to 36, 5 weeks and quota for 36 weeks already met. To ensure there isan adequate proportion of women presenting at 34 to 35 weeks of gestation, enrollmentwill be restricted so that no more than 50% of the women in the trial present at 36weeks.

Study Design

Total Participants: 2831
Study Start date:
October 01, 2010
Estimated Completion Date:
August 31, 2022

Study Description

The rate of preterm birth has steadily increased in the United States over the past 10 years. This increase is driven in part by the rising rate of late preterm birth, defined as those births occurring between 34 and 36 weeks. Late preterm infants experience a higher rate of readmission than their term counterparts, and these infants are more likely to suffer complications such as respiratory distress, kernicterus, feeding difficulties, and hypoglycemia. Late preterm infants also have a higher mortality for all causes when compared to term infants. The use of antenatal corticosteroids has been shown to be beneficial in women at risk for preterm delivery prior to 34 weeks but has not been evaluated in those likely to deliver in the late preterm period. If shown to reduce the need for respiratory support and thus to decrease the rate of special care nursery admissions and improve short-term outcomes, the public health and economic impact will be considerate.This protocol describes a randomized placebo controlled trial to evaluate whether antenatal corticosteroids can decrease the rate of neonatal respiratory support, thus decreasing the rate of neonatal intensive care unit (NICU) admissions and improving short-term outcomes in the late preterm infant.

Two follow-up studies will be conducted concurrently. The first follow-up study will examine if the positive effects of betamethasone on lung function will persist in children at 6 years of age of mothers randomized to betamethasone with an expected late preterm delivery. Neonatal respiratory morbidity is associated with an increased risk of adverse childhood respiratory disease. Thus it is quite plausible that the effect of betamethasone, in reducing neonatal morbidity, particularly TTN, will translate into improved respiratory morbidity in early childhood.The primary outcome is childhood respiratory disease defined by a composite outcome of abnormal pulmonary function test (PFT) measured by spirometry, physician diagnosis of asthma, or other respiratory illnesses with medication.

The second follow-up study will examine whether late preterm antenatal betamethasone treatment is associated with long-term neurocognitive functioning, and whether there are any long-term consequences of what is believed to be transient neonatal hypoglycemia. Cognitive function will be measured by the Differential Ability Scales 2nd Edition (DAS-II) core components of the general conceptual ability (GCA) that includes verbal ability, non-verbal reasoning ability and spatial ability. The primary outcome is defined as a GCA score of <85 (1 standard deviation below the mean) at 6 years of age or greater.

Connect with a study center

  • University of Alabama - Birmingham

    Birmingham, Alabama 35233
    United States

    Site Not Available

  • Stanford University

    Stanford, California 94305
    United States

    Site Not Available

  • University of Colorado

    Denver, Colorado 80045
    United States

    Site Not Available

  • Northwestern University

    Chicago, Illinois 60611
    United States

    Site Not Available

  • Wayne State University

    Detroit, Michigan 48201
    United States

    Site Not Available

  • Columbia University

    New York, New York 10032
    United States

    Site Not Available

  • University of North Carolina - Chapel Hill

    Chapel Hill, North Carolina 27599
    United States

    Site Not Available

  • Duke University

    Durham, North Carolina 27710
    United States

    Site Not Available

  • Case Western Reserve University

    Cleveland, Ohio 44109
    United States

    Site Not Available

  • Ohio State University

    Columbus, Ohio 43210
    United States

    Site Not Available

  • Oregon Health & Science University

    Portland, Oregon 97239
    United States

    Site Not Available

  • University of Pittsburgh Magee Womens Hospital

    Pittsburgh, Pennsylvania 15213
    United States

    Site Not Available

  • Brown University

    Providence, Rhode Island 02905
    United States

    Site Not Available

  • University of Texas - Southwest

    Dallas, Texas 75235
    United States

    Site Not Available

  • University of Texas - Galveston

    Galveston, Texas 77555
    United States

    Site Not Available

  • University of Texas - Houston

    Houston, Texas 77030
    United States

    Site Not Available

  • University of Utah Medical Center

    Salt Lake City, Utah 84132
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.